Introduction Protherics is a biopharmaceutical company focused on developing, manufacturing and marketing critical care and cancer products. The company has two in-house FDA approved products, CroFab and DigiFab. Protherics also has a pipeline of five clinical trial programs and three preclinical programs. Scope - Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights Protherics has developed and manufactured two proprietary biologics for critical care: CroFab, pit viper antivenom; and DigiFab, digoxin antidote. In addition, two unpartnered drug candidates, ViperaTAb and Voraxaze are waiting for FDA approval. The company’s strategic collaborations strengthen its product portfolio.During 2003-2007, the company derived its revenues from product sales, royalties, licensing and collaboration. The company’s total revenues grew at a CAGR of 29% from $21 million to $59 million, primarily due to the milestone payment from the company’s collaboration agreement with AstraZeneca for CytoFab.The acquisition of MacroMed in January 2007 has strengthened Protherics’s pipeline and has provided access to OncoGel for oesophageal and brain cancers. The company in-licensed acadesine (for B-cell chronic lymphocytic leukemia) from Advanced in Vitro Cell Technologies which further developed its product pipeline. Reasons to Purchase - Access all the important information and analysis on the company in a single report
- Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to company’s adjusted five year financial data along with key ratios and market capitalization
TABLE OF CONTENTS Overview 1
Catalyst 1
Summary 1
Company Structure 6
Company Overview and Key Facts 6
Business Description 7
History 9
Locations and Subsidiaries 12
Company Financials 13
Stock Market Performance 13
P&L 15
Balance Sheet 19
Cash Flow 19
Products & Services 20
Marketed Products 20
Pipeline Products 22
Historical Product Sales 26
Competitors and Strategic Business Relationships 27
Key Competitors 27
Key Suppliers 28
Key Clients 28
Shareholding Structure 30
Strategy 31
Company View 31
Corporate Strategy 34
SWOT Analysis 36
Overview 36
Strengths 37
Weaknesses 38
Opportunities 39
Threats 41
Value Chain Analysis 42
Overview 42
Discovery and Product Development 43
Manufacturing 43
Sales 43
Key Employees 44
List of Key Employees 44
Key Employee Biographies 45
Financial and Operational Overview 50
Financial and Operational Overview 50
APPENDIX 52
Ask the analyst 52
Datamonitor consulting 52
Disclaimer 52
TABLE OF FIGURES
Figure 1: Protherics - Key Strategic Revenues, 2003-2007 ($ Mn) 16
Figure 2: Protherics - Operating Revenue/Cost Analysis, 2003-2007 ($ Mn) 17
TABLE OF TABLES
Table 1: Protherics - Key Facts 6
Table 2: Protherics - Locations and Subsidiaries 12
Table 3: Protherics - Year-End Share Price and Market Capitalization, 2003-2007 (œ) 13
Table 4: Protherics - Key Events Impacting Share Price Performance 14
Table 5: Protherics - Operating Revenue/Cost Analysis, 2003-2007 ($ Mn) 15
Table 6: Protherics - Operating Cost Ratio Analysis, 2003-2007 (% of total revenues) 18
Table 7: Protherics - Balance Sheet, 2003-2007 ($ Mn) 19
Table 8: Protherics - Cash Flow, 2003-2007 ($ Mn) 19
Table 9: Protherics - Marketed Products 20
Table 10: Protherics - In-house Pipeline Products 22
Table 11: Protherics - Collaboration Products 23
Table 12: Protherics - Historical Product Sales, 2003-2007 ($ Mn) 26
Table 13: Protherics - Key Competitors 27
Table 14: Protherics - Key Suppliers 28
Table 15: Protherics - Key Clients 29
Table 16: Protherics - Key Shareholders 30
Table 17: Protherics - SWOT Analysis Summary 36
Table 18: Protherics - Value Chain Analysis 42
Table 19: Protherics - Key Employees 44
Table 20: Protherics- Financial and Operational Overview 50
Pages: 52
|
